Northern Trust Corp Raises Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Northern Trust Corp boosted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 5.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 327,815 shares of the medical instruments supplier’s stock after purchasing an additional 15,843 shares during the quarter. Northern Trust Corp’s holdings in LeMaitre Vascular were worth $30,205,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its holdings in shares of LeMaitre Vascular by 48.2% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier’s stock worth $1,227,000 after purchasing an additional 4,330 shares during the last quarter. Invesco Ltd. raised its stake in shares of LeMaitre Vascular by 50.5% during the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier’s stock valued at $16,124,000 after buying an additional 58,720 shares during the last quarter. Barclays PLC lifted its holdings in shares of LeMaitre Vascular by 394.5% in the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock valued at $3,396,000 after buying an additional 29,180 shares during the period. Compass Planning Associates Inc purchased a new stake in shares of LeMaitre Vascular in the fourth quarter worth about $567,000. Finally, Teacher Retirement System of Texas grew its holdings in LeMaitre Vascular by 31.8% during the fourth quarter. Teacher Retirement System of Texas now owns 101,851 shares of the medical instruments supplier’s stock worth $9,385,000 after acquiring an additional 24,586 shares during the period. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Down 1.6 %

LMAT stock opened at $80.20 on Friday. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The firm has a 50-day simple moving average of $84.15 and a 200-day simple moving average of $93.09. The stock has a market capitalization of $1.81 billion, a P/E ratio of 43.83, a P/E/G ratio of 2.22 and a beta of 0.86.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). The firm had revenue of $59.87 million for the quarter, compared to analysts’ expectations of $57.61 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. LeMaitre Vascular’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.44 earnings per share. On average, analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th will be paid a dividend of $0.20 per share. The ex-dividend date is Thursday, May 15th. This represents a $0.80 annualized dividend and a yield of 1.00%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 40.40%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price objective for the company. Finally, Lake Street Capital lifted their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Five research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $98.14.

Insider Transactions at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,009 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company’s stock, valued at approximately $456,915.68. This represents a 26.53 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.